Abstract 70P
Background
Recently, the intratumor mycobiome has been characterized in 17,401 cancer patients, covering 35 cancer types from The Cancer Genome Atlas ( Narunsky-Haziza et al., 2022 ), revealing a previously overlooked aspect of cancer research. Moreover, Recent study showed that race is a key determinant of the human intratumor microbiome. We aimed to better understand the effects of patients’ demographic factors (age, sex, and race) on the intratumor mycobiome composition.
Methods
We analyzed the Narunsky-Haziza et al. de-contaminated and normalized intratumor fungal abundance data for 11 cancer types and 224 fungal species. We performed a systematic characterization of the tumor mycobiome across different cancer types using a propensity score algorithm, adjusting for the potential confounding factors of histological type and tumor stage.
Results
Fungus species abundances differed significantly between races in all cancer types. For example, in breast cancer, we identified 42 significantly differentially abundant fungal species in European vs. Asian, 45 species in European vs. African, and 56 in Asian vs. African. Notably, 19 fungal species Talaromyces marneffei, Scheffersomyces stipites, Debaryomyces fabryi, Lachancea lanzarotensis, Ogataea polymorpha, Tetrapisispora blattae, Fusarium proliferatum, Kazachstania Africana, Torulaspora delbrueckii, Naumovozyma castellii, Wickerhamomyces anomalus, Yamadazyma tenuis, Naumovozyma dairenensis, Sugiyamaella lignohabitans, Clavispora lusitaniae, Candida tropicalis, Vanderwaltozyma polyspora, Meyerozyma guilliermondii, Lachancea thermotolerans – had significantly different abundances in all three race comparisons. Moreover, regarding age (>65) and sex, only 5 fungal species abundance in stomach adenocarcinoma varied significantly for age and Malassezia sympodialis differed significantly with respect to sex. In thyroid carcinoma, 3 species varied by age and Cordyceps militaris for sex.
Conclusions
Our research reveals that the composition of the fungal community within tumors varies significantly across races, underscoring the importance of accounting for this demographic factor when conducting fungal-related analysis and clinical trials involving microbiota modulation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Edmond J. Safra Bioinformatics Center in Tel-Aviv University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09